"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 2 | 3 | 5 |
| 1997 | 3 | 5 | 8 |
| 1998 | 9 | 5 | 14 |
| 1999 | 1 | 1 | 2 |
| 2000 | 5 | 3 | 8 |
| 2001 | 8 | 3 | 11 |
| 2002 | 12 | 6 | 18 |
| 2003 | 3 | 10 | 13 |
| 2004 | 9 | 9 | 18 |
| 2005 | 11 | 7 | 18 |
| 2006 | 6 | 14 | 20 |
| 2007 | 9 | 9 | 18 |
| 2008 | 8 | 21 | 29 |
| 2009 | 9 | 7 | 16 |
| 2010 | 13 | 8 | 21 |
| 2011 | 2 | 2 | 4 |
| 2012 | 6 | 8 | 14 |
| 2013 | 8 | 9 | 17 |
| 2014 | 15 | 10 | 25 |
| 2015 | 10 | 13 | 23 |
| 2016 | 13 | 5 | 18 |
| 2017 | 19 | 10 | 29 |
| 2018 | 9 | 12 | 21 |
| 2019 | 7 | 10 | 17 |
| 2020 | 12 | 10 | 22 |
| 2021 | 10 | 11 | 21 |
| 2022 | 2 | 9 | 11 |
| 2023 | 1 | 9 | 10 |
| 2024 | 5 | 8 | 13 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant. Pediatr Transplant. 2025 Feb; 29(1):e70018.
-
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial. Arthritis Rheumatol. 2025 May; 77(5):571-581.
-
Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation. Am J Hematol. 2025 Mar; 100(3):383-392.
-
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703. J Clin Oncol. 2025 Mar 10; 43(8):912-918.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
-
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints. J Cardiovasc Magn Reson. 2025 Summer; 27(1):101121.
-
Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 2025 Jan; 107(1):21-32.
-
Optimization and Protection of Kidney Health in Liver Transplant Recipients: Intra- and Postoperative Approaches. Transplantation. 2025 Jun 01; 109(6):938-944.
-
Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology. 2024; 240(5-6):897-909.